Synergistic antibiotic peptides

Synergistic peptides with existing antibiotic combinations for gram negative pathogens

Omnicin develops peptides that allow passage of antibiotics across the outer membrane. Combining these peptides with antibiotics such as vancomycin, used against Gram-pos bacteria, we can now efficiently eradicate resistant Gram-neg bacteria

Innovative, cost-effective, use of existing antibiotics against Gram-pos bacteria, virtually new class of antibiotics against Gram-neg bacteria

Technology:
  • Antimicrobial compounds

Microorganisms:
  • Bacteria

Development stage:
  • Development

Organization:
  • Company

Partnering:
  • Yes

Venture Capital consortium and/or major pharmaceutical company

Omnicin Therapeutics BV is a Dutch pharma-biotech start-up, privately owned, with an exclusive license from the University of Groningen

N.A.


What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!